ClinicalTrials.gg
RecruitingNCT05216328OMAMAUpdated Nov 16, 2026

Prevention of Opioid-induced Constipation in Patients With Advanced Cancer

A Phase 4 interventional study of Macrogol Only Product in Oral Dose Form and Magnesium hydroxide 724mg in Constipation, Opioid-Induced, sponsored by Amsterdam UMC, location VUmc. Recruiting at 13 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Amsterdam UMC, location VUmc · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.
Updated Nov 16, 2026Study documents postedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequences that range from daily discomfort with social insecurity and disability to intestinal obstruction. It leads to limitations in self-management, a reduced quality of life and a risk of the need for more care. In the guideline "Diagnosis and treatment of pain in patients with cancer" it is recommended to start preventively with an osmotic laxative such as macrogol/electrolytes or magnesium hydroxide when starting opioids. Macrogol/electrolytes has been proven to be effective for OIC, but is sometimes perceived by patients as unpleasant due to its taste. Magnesium hydroxide, which is less commonly prescribed for OIC, has a neutral taste. Although it is mentioned in the guideline, it is not studied for the treatment of OIC and also not officially registered for this. To support the advice of the guideline and to prove that a choice is possible, it is important to investigate whether there are differences in effectiveness and/or side effects between macrogol/electrolytes and magnesium hydroxide in the prevention of OIC.

The aim of this study is to compare macrogol/electrolytes with magnesium hydroxide in the prevention of opioid-induced constipation in patients with cancer in the palliative (incurable) phase, who start opioids because of pain. The choice of laxative is determined by drawing lots (randomisation). After two weeks, its effect will be assessed and will be presented as the percentage of patients who have not developed constipation after starting opioids. If the laxative, as assigned by lot, is described as satisfactory by the patient, the patient can continue with the drug that the patient used, after the study through regular prescription.

The investigators will ask the patients in the study about their satisfaction with the laxative used, any side effects and the degree of pain. Furthermore, the appeal to care for possible constipation will be examined. Because the best attainable quality of life in the palliative phase is the objective of all care, the investigators will also measure this perceived quality with a questionnaire in this study. The results of this study will lead to the best achievable prevention of opioid constipation in patients with cancer in the palliative phase.

02

Conditions studied

  • Constipation, Opioid-Induced

Keywords

  • Cancer
  • Palliative care
  • Cancer pain
  • Opioid-Induced Constipation
  • macrogol/electrolytes
  • magnesium hydroxide
03

In context

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

This study's planned enrollment of 258 is above the median of 119 across 68 interventional studies indexed under Opioid-Induced Constipation.

Browse Opioid-Induced Constipation studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Patients with advanced cancer (≥18 years);
  • Starting with slow release or transdermal opioids for pain;
  • Able to complete a Dutch questionnaire. Previous treatment with opioids is allowed, if discontinued more than 4 weeks ago.

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Patients with for laxatives
  • Maintenance treatment with laxatives during the last 14 days
  • Severely impaired renal function (serum creatinine >180 umol/l)
  • Estimated \<1 month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Active comparator
    Macrogol/electrolytes

    Macrogol/electrolytes is started at a dose of 1 sachet once a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of macrogol/electrolytes may be increased to 2 sachets a day during the study period. The effect of laxatives will be judged after 14 days.

    Drug: Macrogol Only Product in Oral Dose Form

  • Active comparator
    Magnesium hydroxide

    Magnesium hydroxide is started at a dose of 724 mg three times a day orally, based on the current guideline 'Diagnosis and treatment of pain in patients with cancer' (www.pallialine.nl). The dose of magnesium hydroxide may be increased to 1448 mg three times a day during the study period. The effect of laxatives will be judged after 14 days.

    Drug: Magnesium hydroxide 724mg

Interventions

  • DrugMacrogol Only Product in Oral Dose Form

    Information already included in arm/group description.

    Also known as: Macrogol/electrolytes

  • DrugMagnesium HydroxideStudies of Magnesium HydroxideMagnesium Hydroxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Information already included in arm/group description.

    Also known as: Magnesiumoxide

06

What researchers measure

Primary outcomes

  1. The percentage of patients with a score of <30 of the Bowel Function Index

    A clinician-administered patient-reported questionnaire to assess clinically significant constipation, validated in patients receiving opioids for chronic non-malignant pain and for malignant pain (Abramovitz 2013, Rentz 2009 and 2011). It consists of three questions, assessing ease of defecation, feeling of incomplete bowel evacuation and personal judgement of the patient regarding constipation, each during the last 7 days and each rated on a scale of 0 (best possible outcome) to 100 (worst possible outcome). A total score ≥30 (mean of the three separate scores) indicates clinically significant constipation. A change of the total score of \>12 is regarded as clinically meaningful. It has been used in a large observational study in cancer patients receiving opioids (Davies 2021) and in randomised trials of opioid antagonists for OIC (Ahmedzai 2012, Dupoiron 2017, Leng 2020, Poelaert 2015). It has been recommended as the assessment tool of choice for OIC (Argoff 2015, Farmer 2019).

    Time frame: On day 14

Secondary outcomes

  1. The EQ5D

    A self-administered, generic assessment tool developed by the EuroQol Group, a network of international research teams, and consists of questions on five dimensions of health (i.e., mobility, self-care, pain/discomfort, usual activities, and anxiety/depression) (Pickard 2007). It has been used in cost-effectiveness studies on OIC (Dunlop 2012, Hjalte 2016, Lawson 2016).

    Time frame: On day 0 and day 14

  2. Rome IV criteria for opioid-induced constipation

    Rome IV criteria for opioid-induced constipation as judged by professional care givers (Davies 2021, Drossman 2016), including: * straining during \>25% of defecations * lumpy or hard stools in \>25% of defecations * sensation of incomplete evacuation in \>25% of defecations * sensation of anorectal obstruction/blockage in \>25% of defecations * manual manoeuvres to facilitate \>25% of defecations * \<3 spontaneous defecations per week At least two of these criteria have to be fulfilled in order to diagnose constipation, to be judged by the treating physician or clinical nurse specialists/nurse practitioners

    Time frame: On day 0 and day 14

  3. Cancer pain score

    Numeric Rating SDcale, ranging from 0 to 10

    Time frame: On day 0 and day 14

  4. Patient satisfaction with laxative

    A single four-item question, ranging from unsatisfied to very satisfied.

    Time frame: On day 14

  5. Side effects of laxatives

    All side-effects are scored on a four-point Likert scale (not at all, a bit, rather, very much): * Bad taste * Problems with swallowing * Abdominal cramps * Nausea * Flatulence * Diarrhea * Other (to be specified by the patient)

    Time frame: On day 14

  6. Cost-effectiveness of macrogol/electrolytes compared to magnesium hydroxide

    We aim to perform a comparative cost-effectiveness of the laxatives. This requires data collection on healthcare procedures and QOL in responders, non-responders and patients with side-effects of laxatives for the follow-up period of the study. These healthcare procedures will be extracted from hospital databases and healthcare use outside the hospital will be collected with the iMCQ at 4 weeks. All individual health care procedures will be linked to their unit costs. Reimbursement prices issued by the Dutch Healthcare Authority and national reference prices will be used for this assessment as outlined in current Dutch pharmaco-economic guidance. The cost-effectiveness analysis will be performed using a decision tree including different branches for initial therapy and responders and non-responders. The costs and QOL of the patients in the trial will be used as input for this decision tree. Total costs and effects will be calculated by summing the costs and effects of each branch.

    Time frame: On day 14

07

Study locations

13 of 13 sites recruiting
08

References and documents

Publications

  • Abramowitz L, Beziaud N, Causse C, Chuberre B, Allaert FA, Perrot S. Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC). J Med Econ. 2013 Dec;16(12):1434-41. doi: 10.3111/13696998.2013.851083. Epub 2013 Oct 24. PubMed 24102611 ↗
  • Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012 Jan;26(1):50-60. doi: 10.1177/0269216311418869. Epub 2011 Sep 21. PubMed 21937568 ↗
  • Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. Pain Med. 2015 Dec;16(12):2324-37. doi: 10.1111/pme.12937. Epub 2015 Nov 19. PubMed 26582720 ↗
  • Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009 May-Jun;5(3):137-44. doi: 10.5055/jom.2009.0014. PubMed 19662923 ↗
  • Christensen HN, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain. 2016 Apr;11:104-110. doi: 10.1016/j.sjpain.2015.12.007. Epub 2016 Jan 25. PubMed 28850447 ↗
  • Davies A, Leach C, Butler C, Gregory A, Henshaw S, Minton O, Shorthose K, Batsari KM. Opioid-induced constipation in patients with cancer: a "real-world," multicentre, observational study of diagnostic criteria and clinical features. Pain. 2021 Jan;162(1):309-318. doi: 10.1097/j.pain.0000000000002024. PubMed 32701649 ↗
  • Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Portenoy R. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2013 May;27(5):447-56. doi: 10.1177/0269216312450358. Epub 2012 Jun 15. PubMed 22707180 ↗
  • Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19:S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032. Online ahead of print. PubMed 27144617 ↗
  • Dunlop W, Uhl R, Khan I, Taylor A, Barton G. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ. 2012;15(3):564-75. doi: 10.3111/13696998.2012.665279. Epub 2012 Feb 23. PubMed 22313329 ↗
  • Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. Eur J Pain. 2017 Oct;21(9):1528-1537. doi: 10.1002/ejp.1054. Epub 2017 Jun 22. PubMed 28641363 ↗
  • Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O'Brien T, Morlion B, Tack J. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019 Feb;7(1):7-20. doi: 10.1177/2050640618818305. Epub 2018 Dec 14. PubMed 30788113 ↗
  • Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997 Oct;37(10):904-7. doi: 10.1002/j.1552-4604.1997.tb04264.x. PubMed 9505981 ↗
  • Ginex PK, Hanson BJ, LeFebvre KB, Lin Y, Moriarty KA, Maloney C, Vrabel M, Morgan RL. Management of Opioid-Induced and Non-Opioid-Related Constipation in Patients With Cancer: Systematic Review and Meta-Analysis. Oncol Nurs Forum. 2020 Nov 1;47(6):E211-E224. doi: 10.1188/20.ONF.E211-E224. PubMed 33063777 ↗
  • Hawley P, MacKenzie H, Gobbo M. PEG vs. sennosides for opioid-induced constipation in cancer care. Support Care Cancer. 2020 Apr;28(4):1775-1782. doi: 10.1007/s00520-019-04944-5. Epub 2019 Jul 18. PubMed 31321524 ↗
  • Head SJ, Kaul S, Bogers AJ, Kappetein AP. Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Heart J. 2012 Jun;33(11):1318-24. doi: 10.1093/eurheartj/ehs099. Epub 2012 May 7. PubMed 22564354 ↗
  • Hjalte F, Ragnarson Tennvall G, Welin KO, Westerling D. Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden. Pain Ther. 2016 Dec;5(2):227-236. doi: 10.1007/s40122-016-0059-9. Epub 2016 Nov 9. PubMed 27830531 ↗
  • Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y; Japanese Study Group for the Relief of Opioid-induced Gastrointestinal Dysfunction. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012 Jun;28(5):373-81. doi: 10.1097/AJP.0b013e318237d626. PubMed 22156893 ↗
  • Lyseng-Williamson KA. Correction to: Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use. Drugs Ther Perspect. 2019;35(1):49. doi: 10.1007/s40267-018-0588-x. Epub 2018 Nov 28. PubMed 31186614 ↗
  • Penning-van Beest FJ, van den Haak P, Klok RM, Prevoo YF, van der Peet DL, Herings RM. Quality of life in relation to constipation among opioid users. J Med Econ. 2010 Mar;13(1):129-35. doi: 10.3111/13696990903584436. PubMed 20128662 ↗
  • Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics. 2007;25(5):365-84. doi: 10.2165/00019053-200725050-00002. PubMed 17488136 ↗
  • Poelaert J, Koopmans-Klein G, Dioh A, Louis F, Gorissen M, Loge D, Van Op den Bosch J, van Megen YJ. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015 Apr 1;37(4):784-92. doi: 10.1016/j.clinthera.2015.02.010. Epub 2015 Mar 7. PubMed 25757607 ↗
  • Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371-83. doi: 10.3111/13696990903430481. PubMed 19912069 ↗
  • Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin. 2011 Jan;27(1):35-44. doi: 10.1185/03007995.2010.535270. Epub 2010 Nov 18. PubMed 21083515 ↗
  • Taylor RR, Guest JF. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. Aliment Pharmacol Ther. 2010 Jan 15;31(2):302-12. doi: 10.1111/j.1365-2036.2009.04191.x. Epub 2009 Nov 3. PubMed 19886948 ↗
  • Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007 Jul;34(1):94-104. doi: 10.1016/j.jpainsymman.2006.10.015. Epub 2007 May 23. PubMed 17509812 ↗
  • Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Akashi Y, Sato H, Kizawa Y. Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. Cancer Med. 2019 Aug;8(10):4883-4891. doi: 10.1002/cam4.2341. Epub 2019 Jun 24. PubMed 31231974 ↗
  • Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care. 2005 Sep-Oct;22(5):375-81. doi: 10.1177/104990910502200511. PubMed 16225360 ↗
  • Kistemaker KRJ, de Graeff A, Crul M, de Klerk G, van de Ven PM, van der Meulen MP, van Zuylen L, Steegers MAH. Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients: study protocol for an open-label, randomized controlled trial (the OMAMA study). BMC Palliat Care. 2023 Mar 14;22(1):22. doi: 10.1186/s12904-023-01143-2. PubMed 36915062 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Due to the sensitivity of the data, the underlying data sets will not be shared publicly but will be made available for verification/ inspection purposes. Additional sharing conditions will be considered (e.g. via the Personal Health Train initiative from Health-RI, which is currently under development) while respecting the type of informed consent provided by the subjects and discussed with the support of Legal/Privacy/RDM experts where appropriate. For descriptive documentation (protocol, data dictionary, syntax/script, etc.) the study team will collaborate with RDM, to ensure such data can be found and made available to other researchers. Providing information in an online (metadata) catalogue that is certified holds preference. We are considering using a DANS repository or similar. DANS EASY is commonly used, uses the Dublin Core Metadata standard, provides a PID and holds a Core Trust Seal. However, DANS is initiatiating Data Stations, with a specific one for the Life Sciences and

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2022 (actual). Primary completion is estimated for Jan 2027, 49 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2025 → Jan 2027 and completion Dec 2025 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Jan 31, 2022
StartActual
Dec 2, 2022
Primary completionEst.
Jan 2027was Dec 2025
CompletionEst.
Jun 2027was Dec 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 9 sites removed
Show 9 added (9 Netherlands)
  • Flevoziekenhuis · Almere Stad, Netherlands
  • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
  • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
  • Spaarne Gasthuis · Hoofddorp, Netherlands
  • University Medical Center Groningen · Groningen, Netherlands
  • Martini Hospital Groningen · Groningen, Netherlands
  • Leiden University Medical Center · Leiden, Netherlands
  • Erasmus Medical Center · Rotterdam, Netherlands
  • University Medical Center Utrecht · Utrecht, Netherlands
Show 9 removed
  • Flevoziekenhuis · Almere, Netherlands
  • Jeroen Bosch Ziekenhuis · 's Hertogenbosch, Netherlands
  • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
  • Spaarne Gasthuis · Hoofddorp, Netherlands
  • Leiden University Medical Center · Leiden, Netherlands
  • Erasmus Medical Center · Rotterdam, Netherlands
  • University Medical Center Groningen · Groningen, Netherlands
  • Martini Hospital Groningen · Groningen, Netherlands
  • University Medical Center Utrecht · Utrecht, Netherlands
Oct 5, 2026
Primary completion
Dec 2025→Jan 2027
Oct 5, 2026
Study completion
Dec 2025→Jun 2027
Oct 5, 2026
Enrollment
330→258
Oct 5, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with metastaticadvanced cancer (≥18 years);
Exclusion criteria
  • ChangedBefore Use of laxatives during the last four weeksNow Maintenance treatment with laxatives during the last 14 days
  • EditedEstimated life expectancy <3 months1 month
Oct 5, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36915062 ↗
Oct 5, 2026
Sponsor
Collaborators added: Antoni van Leeuwenhoek Hospital; collaborators removed: Antoni van Leeuwenhoekziekenhuis (AVL) Amsterdam
Oct 5, 2026
Show all 2 updates
  1. Nov 16, 2026
    + 1 other change: verification date
  2. Oct 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36915062 ↗
    9 sites added, 9 sites removed
    Show 9 added (9 Netherlands)
    • Flevoziekenhuis · Almere Stad, Netherlands
    • Jeroen Bosch Ziekenhuis · 's-Hertogenbosch, Netherlands
    • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
    • Spaarne Gasthuis · Hoofddorp, Netherlands
    • University Medical Center Groningen · Groningen, Netherlands
    • Martini Hospital Groningen · Groningen, Netherlands
    • Leiden University Medical Center · Leiden, Netherlands
    • Erasmus Medical Center · Rotterdam, Netherlands
    • University Medical Center Utrecht · Utrecht, Netherlands
    Show 9 removed
    • Flevoziekenhuis · Almere, Netherlands
    • Jeroen Bosch Ziekenhuis · 's Hertogenbosch, Netherlands
    • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
    • Spaarne Gasthuis · Hoofddorp, Netherlands
    • Leiden University Medical Center · Leiden, Netherlands
    • Erasmus Medical Center · Rotterdam, Netherlands
    • University Medical Center Groningen · Groningen, Netherlands
    • Martini Hospital Groningen · Groningen, Netherlands
    • University Medical Center Utrecht · Utrecht, Netherlands
    Primary completion Dec 2025→Jan 2027
    Study completion Dec 2025→Jun 2027
    Enrollment 330→258
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with metastaticadvanced cancer (≥18 years);
    Exclusion criteria
    • ChangedBefore Use of laxatives during the last four weeksNow Maintenance treatment with laxatives during the last 14 days
    • EditedEstimated life expectancy <3 months1 month
    Sponsor Collaborators added: Antoni van Leeuwenhoek Hospital; collaborators removed: Antoni van Leeuwenhoekziekenhuis (AVL) Amsterdam
    + 3 other changes: index terms, verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05216328
Collaborators
Leiden University Medical Center, University Medical Center Groningen, Radboud University Medical Center, Erasmus Medical Center, Spaarne Gasthuis, Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Martini Hospital Groningen, Haaglanden Medical Centre, UMC Utrecht, Groene Hart Ziekenhuis, Bernhoven Hospital, Isala, Antoni van Leeuwenhoek Hospital
Responsible party
Lia van Zuylen (Prof. Dr., Amsterdam UMC, location VUmc) — Principal investigator
First posted
Jan 31, 2022
Start date
Dec 2, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Kay Kistemaker, MSc/MD
Contact
k.kistemaker@amsterdamumc.nl
+31 6 50087799
Lia van Zuylen, Prof. dr.
Contact
c.vanzuylen@amsterdamumc.nl
+3120 4445571
Lia van Zuylen, Prof.dr.
principal investigator · Amsterdam UMC, location VUmc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Hydroxide

Start the discussion